Benzinga | May 3, 2021 04:06PM EDT

Myriad Genetics Q3 Adj. EPS $(0.06) Beats $(0.14) Estimate, Sales $173.10M Beat $156.20M Estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by 57.14 percent. This is a 25 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $173.10 million which beat the analyst consensus estimate of $156.20 million by 10.82 percent. This is a 5.55 percent increase over sales of $164.00 million the same period last year.